Lilly’s retatrutide shows substantial weight loss and A1C reduction
Lilly’s triple agonist retatrutide delivered substantial weight loss and A1C reduction, underscoring potential promise for people with obesity and type 2 diabetes.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.